3.238.204.31
dgid:
enl:
npi:0
Alagille Syndrome
FDA Alerts
Genetic and congenital
Hematology
Trending Topics

FDA Approves First Therapy for Children with Neurofibromatosis Type 1

Posted on April 12, 2021
FDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus Vulgaris

The U.S. Food and Drug Administration has approved selumetinib (Koselugo) for the treatment of pediatric patients, ≥2 years of age, with neurofibromatosis type 1 (NF1). This is the first drug approved by the FDA to treat NF1.

NF1 is a genetic disorder of the nervous system that causes tumors to grow on nerves.

Approval was based on a clinical trial conducted by the National Cancer Institute of pediatric patients who had NF1 and inoperable plexiform neurofibromas (PN). Fifty patients received selumetinib 25 mg/m2 orally twice a day until disease progression or until they experienced unacceptable adverse reactions. The overall response rate was 66%, with all patients experiencing a partial response. No patients had complete disappearance of the tumor.

Read the full press release here.

Source: FDA